Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Canadian Sec - Delayed Quote CAD

MindBio Therapeutics Corp. (MBIO.CN)

Compare
0.0100
0.0000
(0.00%)
At close: 2:12:28 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MBIO.CN

Recent News: MBIO.CN

View More
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
ACCESS Newswire 7 months ago

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
ACCESS Newswire 8 months ago
MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
ACCESS Newswire 9 months ago
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
ACCESS Newswire 9 months ago
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
ACCESS Newswire 10 months ago
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month

MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
ACCESS Newswire 11 months ago
MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3

MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
ACCESS Newswire 11 months ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials

MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
ACCESS Newswire 11 months ago
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry

MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
ACCESS Newswire 11 months ago
Lender Requests to Convert Loan to MindBio Shares

Lender Requests to Convert Loan to MindBio Shares
ACCESS Newswire 11 months ago
View More

Related Tickers

PSH0.F Sernova Biotherapeutics Inc
0.1160
+14.85%
 
XRTX.V XORTX Therapeutics Inc.
1.1500
-4.17%
 
GLOW.CN Glow Lifetech Corp.
0.0650
0.00%
 
XRTX XORTX Therapeutics Inc.
0.8500
-5.24%
 
GRTX Galera Therapeutics, Inc.
0.0241
-3.60%
 
PHRM.CN PharmaTher Holdings Ltd.
0.2100
+10.53%
 
OKUR OnKure Therapeutics, Inc.
2.9500
-0.34%
 
XBIO Xenetic Biosciences, Inc.
2.3000
-3.77%
 
OPT Opthea Limited
3.4100
+1.49%
 
BOLT Bolt Biotherapeutics, Inc.
0.3237
+0.84%